ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1383

Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

Rebecca Olveda, Jessica Neely and Susan Kim, UCSF Benioff Children's Hospital, San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: dermatomyositis, Disparities, Patient reported outcomes, Pediatric rheumatology, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have worse clinical outcomes. Patient-reported outcome measures (PROs) are valuable indicators of disease activity but are less well-studied in JDM. This study aimed to investigate differences in clinical outcomes and PROs based on race and ethnicity at baseline and at 12 months, in a cohort of patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.

Methods: This was a retrospective cohort study using data from children diagnosed with JDM and enrolled into the CARRA Registry between February 2018 and November 2021, for whom data regarding race and ethnicity were available. The primary predictor was self-identified race and/or ethnicity. The primary outcome was the Patient/Parent Global Assessment Score (PGA) as a dichotomous variable of score < /= 2 (lower disease activity) or > 2 (higher disease activity). Secondary outcomes included proximal muscle weakness, elevated muscle enzymes, and PGA score at 12 months. Descriptive statistics were used to summarize each variable, and demographic and baseline disease activity measures were evaluated across racial and ethnic categories using Chi-squared and Kruskal-Wallis tests. Demographic variables with significant association with race and ethnicity were included in a multivariate model analyzing PGA score greater than 2 at baseline.

Results: 250 participants identified as Asian (5.6%), Black (11.2%), Hispanic (18.4%), or White (64.8%). Demographic characteristics are listed in Table 1. A higher proportion of Black and Hispanic participants were in the lowest income brackets (p = 0.04) (Table 1). At baseline, Asian, Black, and Hispanic participants were more likely to have proximal muscle weakness (p = 0.01) and elevated muscle enzymes compared to White participants (p = 0.04) (Table 2). Black participants had 3.1 times the odds of having a PGA > 2 at baseline compared to White participants (95% CI 1.2 to 7.8, p = 0.02). After adjusting for age at diagnosis, income, education, and insurance status, this association was no longer statistically significant. White participants tended to have lower PGA scores at baseline and at 12 months compared to Black and Asian participants. However, PGA score at 12 months and change in PGA score over 1 year were not significantly different between racial and ethnic groups (Figure 1).

Conclusion: In JDM participants enrolled in the CARRA Registry, Black and Hispanic participants tended to have lower income and education levels. While Black participants had a higher odds of having worse PGA at baseline, this association diminished after adjusting for age at diagnosis, income, education, and insurance status. Our study was limited by a smaller proportion of participants from minoritized racial and ethnic groups. More research is needed to determine how patient outcomes are influenced by social determinants of health, including income, education, and the effects of systemic racism, in order to inform future interventions to improve health disparities.

Supporting image 1

Table 1: Baseline demographic characteristics by race and ethnicity
*FPL = below the federal poverty limit (FPL) for a family of 4 in 2019, which was approximately $25,750, per the US Census Bureau.

Supporting image 2

Table 2: Baseline disease characteristics and patient-reported outcomes.

*A physician global assessment (PhGA) or patient/parent global assessment (PGA) score greater than 2 indicates worse disease activity.
ƚ CHAQ = Childhood Health Assessment Questionnaire; score range of 0 to 3, with higher scores indicating worse disease activity
ǂ Patient-Reported Outcomes Measurement Information System (PROMIS) measures
a. Pain Interference: patient-reported measurement of how much pain associated with activity impacts daily life, with a score range of 0 to 32, with higher scores indicating worse disease activity
b. Physical function – mobility: patient-reported measurement of mobility, with a score range of 0 to 32, with higher scores indicating worse disease activity
c. Physical function – upper extremity: patient-reported measurement of degree of limitation of physical function of the upper extremities, with a score range of 0 to 32, with higher scores indicating worse disease activity

Supporting image 3

Figure 1: Change in median PGA score from baseline to 12 months by race and ethnicity


Disclosures: R. Olveda, None; J. Neely, None; S. Kim, None.

To cite this abstract in AMA style:

Olveda R, Neely J, Kim S. Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/differences-in-clinical-and-patient-reported-outcomes-in-juvenile-dermatomyositis-by-race-and-ethnicity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-clinical-and-patient-reported-outcomes-in-juvenile-dermatomyositis-by-race-and-ethnicity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology